Portage Biotech's PORT-7 shows efficacy in mesothelioma preclinical study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Preclinical Efficacy of PORT-7: Portage Biotech's PORT-7, a selective adenosine A2B receptor inhibitor, showed superior efficacy in a murine mesothelioma model compared to anti-PD1 antibody alone, with enhanced immune responses observed when combined with anti-PD1 treatment.
Clinical Trial Preparations: Portage is preparing to initiate a first-in-human clinical trial for PORT-7 while also advancing the dose escalation of PORT-6, aiming to eventually co-administer both drugs in the ongoing ADPORT-601 trial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
